中国药房2012，Vol.23Issue(35)：3353-3355,3.DOI:10.6039/j.issn.1001-0408.2012.35.33
血必净注射液联合TACE治疗原发性肝癌的临床疗效观察
Clinical Observation of Xuebijing Injection Combined with TACE on Primary Liver Cancer
王高强 1吴孝雄 1吴胜兵 1孙保木 1陈挺松 1时良慧 1罗明1
作者信息
- 1. 第二军医大学东方肝胆外科医院中西医结合科,上海200438
- 折叠
摘要
Abstract
OBJECTIVE: To investigate the clinical efficacy of Xuebijing injection combined with TACE on primary liver cancer. METHODS: 92 patients with primary liver cancer were randomly divided into combination group (n=47) and control group (n=45). Control group was given conventional TACE treatment (iodipin embolization+local chemotherapy + symptomatic treatment) , and combination group was additionally given Xuebijing injection 50 mL added in 0.9% Sodium chloride injection l00 mL once a day for consecutive 7 days on the basis of TACE treatment. Changes of body temperature, liver and renal function, blood routine tests and AFP were all detected, and short-term efficacy and acute toxicity reaction were compared between 2 groups. RESULTS: Compared with before treatment, AFPs in combination group and control group were both decreased significantly (P＜ 0.05). The total effective rates were 91.49% and 88.49% in 2 groups, there was no significant difference between them (P＞0.05). The incidence of complications such as nausea, vomit and abdominal pain in combination group were significantly lower than in control group(P＜0.05). The improvement of toxicity such as fever, lesion of liver and kidney function and bone marrow suppression were significantly better than those in control group (P＜0.05). CONCLUSION: Xuebijing injection can reduce the related toxicity in patients with primary liver cancer treated by TACE obviously and improve the quality of life.关键词
血必净注射液/原发性肝癌/经导管肝动脉化疗栓塞术/疗效/毒性反应Key words
Xuebijing injection/ Primary liver cancer/ TACE/ Effect/ Toxicity分类
医药卫生引用本文复制引用
王高强,吴孝雄,吴胜兵,孙保木,陈挺松,时良慧,罗明..血必净注射液联合TACE治疗原发性肝癌的临床疗效观察[J].中国药房,2012,23(35):3353-3355,3.
